In addition to the deleterious effects on hepatic physiological processes, TMEM16A also exerted systemic effects including obesity, adipocyte hypertrophy, visceral fat weight gain, glucose intolerance, and insulin hyposensitivity, which may be attributed primarily to liver dysfunction. Here, ANO1 is linked to obesity disorder.